Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1.

Abstract

Seven patients with carcinomatous meningitis were administered intrathecal I-131 labelled monoclonal antibody HMFG1. Clinical responses were seen in two patients, with a long term survivor at 32 months. Aseptic meningitis occurred in 4/7 patients, but more serious toxicity was observed in the form of seizures (2/7 patients) and myelosuppression (3/7 patients). Partial obliteration of the subarachnoid space was identified as a potential problem in patients with advanced disease.

• Authors: R P Moseley, J C Benjamin, R D Ashpole, N M Sullivan, J A Bullimore, H B Coakham, J T Kemshead
• Journal: Journal of neurology, neurosurgery, and psychiatry (J Neurol Neurosurg Psychiatry) Vol. 54 Issue 3 Pg. 260-5 (Mar 1991) ISSN: 0022-3050 [Print] England
• PMID: 2030355 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antigens, Neoplasm
• Iodine Radioisotopes
• Membrane Glycoproteins
• Mucin-1

Topics

• Adult
• Antibodies, Monoclonal (therapeutic use)
• Antibody Specificity (immunology)
• Antigens, Neoplasm (immunology)
• Female
• Follow-Up Studies
• Humans
• Iodine Radioisotopes (therapeutic use)
• Male
• Membrane Glycoproteins (immunology)
• Meningeal Neoplasms (diagnostic imaging, radiotherapy, secondary)
• Meningitis (diagnostic imaging, radiotherapy)
• Middle Aged
• Mucin-1
• Neurologic Examination
• Radionuclide Imaging